Dr. Brad McGregor

It doesn't change my management in the perioperative setting today.

Again, I get it in that perioperative setting because I'm worried they're going to relapse.

I want to have the information in the future should they need it.

But I don't think we had any data that we can sort of offer patients some this or that based on some, like, change what treatment we're using based on that.

Yeah, I agree.

I actually expect the data in the cis-eligible population to look markedly better, actually, than we saw in the style, only because you get four cycles in the pre-op map, there's three cycles.

And if you just look at EV in the metastatics, EV per metastatics, and the patients with cisplatin ineligible had a better outcome, right?

So they're just fitter patients, better tolerability, all the therapies, so...

I actually, I do think it's super positive.

And so to that point, I mean, yes, I think, you know, I'm looking for reasons for patients to be cisplatin ineligible in the current era.

You know, I have very, I have patients that have been online coming in, right?

So they're already asking, like, well, can I...

What about ED Pembroke?

I saw this.

I saw this online.

I saw this here, that.

And so I think it's important to have that realistic discussion with the patient.

Like, you know, in a metastatic setting, ED Pembroke beat platinum therapy.

It beat cisplatin.

It beat carboplatin.